A Single-Blind Randomized Trial of Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Locally Advanced Non-Small Cell and Small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 入组人数
- 64
- 试验地点
- 2
- 主要终点
- The pulmonary quality of life at 3 months post-radiotherapy
研究概览
简要总结
Thoracic radiotherapy (TRT) is a standard curative treatment for locally advanced, unresectable non-small cell lung cancer (NSCLC) and limited stage small cell lung cancer (SCLC). TRT has been recognized to cause moderate to severe lung injury in a substantial portion of patients. Conventional standard curative TRT planning techniques minimize the radiation dose to the anatomical lungs, without adaption of regional pulmonary function variations. The principal investigator hypothesized that preferential avoidance of functional lung during curative TRT may decrease the risk of pulmonary toxicity. Functional lung regions are identified using four- dimensional computed tomography for ventilation imaging. This randomized, single-blind trial will comprehensively assess the impact of functional lung avoidance on pulmonary toxicity, quality of life, and clinical outcome in patients receiving curative TRT for locally advanced NSCLC and SCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Functional Lung Avoidance-TRT
Functional Lung Avoidance Thoracic Radiotherapy
The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable
干预措施: Functional Lung Avoidance Thoracic Radiotherapy (Radiation)
Standard-TRT
Standard Thoracic Radiotherapy
The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging
干预措施: Standard Thoracic Radiotherapy (Radiation)
结局指标
主要结局
The pulmonary quality of life at 3 months post-radiotherapy
时间窗: Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months
Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS)
次要结局
- Overall survival(From date of enrollment until the date of death from any cause, assessed up to 60 months)
- Patient reported outcome (Quality of Life questionnaire by EORTC Core)(At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy)
- Acute toxicity(From date of radiotherapy until 90 days after radiotherapy starts)
- Late toxicity(90 days after radiotherapy starts until the date of death from any cause, up to 60 months)
- Patient reported outcome (Quality of Life questionnaire by EORTC Lung cancer)(At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy)
- Changes of pulmonary function test post-radiotherapy(At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy)
- Patient reported outcome (Quality of Life questionnaire by Functional Assessment of Cancer Therapy)(At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy)
- Progression free survival(From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months)